Sunday, December 7, 2025 12/7/2025

A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease

Award Number: K23AA032563
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/16/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2030

Group Awards By:

View Award Description

A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease - Abstract Alcohol use disorder (AUD) is a devastating disease with significant morbidity and mortality, particularly due to alcohol-associated liver disease (ALD). Early intervention and optimal medication adherence to medications for AUD (MAUD) can decrease alcohol use and prevent the progression of liver damage. Yet, adherence to MAUD, especially acamprosate - the preferred medication for AUD in individuals with ALD - remains suboptimal. This K23 proposal seeks to leverage an innovative digital pill system (DPS) that directly measures acamprosate ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention. The DPS will collect real-time adherence data to contextualize and personalize smartphone-delivered adherence support, potentially revolutionizing how adherence is managed in high-risk AUD populations. To achieve this goal, we will 1) develop a user-centered adherence intervention paired with a DPS (AcamproSync) to informed tailored support for participants with ALD and AUD taking acamprosate; 2) test the feasibility and acceptability of AcamproSync through a pilot randomized controlled trial in N=50 individuals with AUD and ALD prescribed acamprosate compared to treatment as usual; and 3) assess user experience and barriers to the implementation of AcamproSync, guided by the Reach-Effectiveness-Adoption, Implementation, and Maintenance (RE-AIM) framework. By addressing key gaps in adherence to MAUD, this project has the potential to significantly impact AUD treatment outcomes. This study will also provide foundational data for the development of a scalable digital health-based intervention to improve adherence that has trans-NIH applicability to other high priority health issues.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $194,062 )
2025	2025	BRIGHAM & WOMENS HOSPITAL INC	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Alcohol Research Programs	000	1	9/16/2025	NEW	$194,062
														Subtotal = $194,062

Grand Total All Awards = $194,062

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A digital pill system to measure and support acamprosate adherence in individuals with alcohol associated liver disease

Award Number: K23AA032563

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/16/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer